About the Author
My name is Mark Senak. I’m a lawyer and I work at the international communications firm FleishmanHillard in New York. For the past several years, I have been consulting with pharmaceutical and biologic companies that are engaged in the process of bringing new drugs to market. I have also worked extensively with an array of medical societies and patient organizations providing strategic communications counsel and media training.Stay Connected
My Profile
I am an authority on regulatory aspects of communications and medical products, with particular emphasis on pre-approval communications; strategist to help pharma and biotech companies prepare best case for advisory committee approval; and counselor in issues and crisis management. I am a frequent speaker on various aspects of same - drug development, promotion, reimbursement and new media in a highly regulated environment. Author of books, newspaper and magazine pieces related to drug marketing and promotion as well as HIV specialty pieces. And of course... blogger!About This Blog
Eye on FDA is published by Mark Senak of FleishmanHillard’s New York office. The thoughts and ideas in this blog and postings are strictly my own and are not screened by my employer. Everything posted on this blog is my personal opinion and does not necessarily represent the views of FleishmanHillard or its clients.
Posts by Date
Twitter List
Legislative Tracking Tools
Monthly Archives: May 2011
Weekly Roundup 5/20/11
I woke up this morning and thought it was Saturday. I went back to sleep. Then I woke up and thought it was Monday. I went back to sleep. Then I woke up and realized it was Friday. Yay. Not … Continue reading
Posted in Weekly Roundup
Comments Off on Weekly Roundup 5/20/11
Making the Most Out of Medical Meetings and Social Media
Yesterday my brilliant friend Brian Reid posted to the WCG Common Sense blog a piece entitled “A Modest Proposal for Socializing ASCO“. In it, he addresses the sheer volume of information that is on display at a medical meeting and … Continue reading
Posted in New and Social Media
3 Comments
AdComm Vacancies and Conflict of Interest Standards
Last week at the Reuter’s Health Summit held in New York, Janet Woodcock, the head of the Center for Drug Evaluation and Research was quoted as saying that she expected drug approvals to increase this year, but that the financial … Continue reading
Posted in Advisory Committee Prepapartion, FDA Policy
Comments Off on AdComm Vacancies and Conflict of Interest Standards
Weekly Roundup – 5/13/11
It is gloomy outside. I am gloomy inside. To distract me, I will report a little of what happened this week: FDA Seeks Input on Development of User Fee Program for Biosimilars – The agency has enunciated principles for the … Continue reading
Posted in Uncategorized
Comments Off on Weekly Roundup – 5/13/11
Valuable Information from Pew; Valuable Insights Result
The Pew Internet & American Life Project today issued another in its continual and valuable series providing us with data on how people are using the Intenet and social media for purposes of navigating their own healthcare and that for … Continue reading
Posted in Uncategorized
Comments Off on Valuable Information from Pew; Valuable Insights Result